Moximox

Moxifloxacin

Bacterial infections in adults (≥18 yr), including URTI (eg, acute exacerbations of chronic bronchitis, community-acquired pneumonia, acute bacterial sinusitis); complicated skin & skin tissue infections, intra-abdominal infections; mild to moderate pelvic inflammatory disease (eg, upper genital tract infections, including salpingitis & endometritis) w/o tubo-ovarium or pelvic abscess.

Adult ≥18 yr Recommended dose: 400 mg once daily. Duration of treatment: Acute exacerbation of chronic bronchitis 5-10 days. Community acquired pneumonia 10 days. Acute sinusitis 7 days. Complicated skin & soft tissue infections 7-21 days (sequential IV/oral therapy). Complicated intra-abdominal infections 5-14 days (sequential IV/oral therapy). Mild to moderate pelvic inflammatory disease 14 days.

May be taken with or without food: Swallow whole w/ adequate water.

Hypersensitivity to moxifloxacin or other quinolones. Patients w/ history of quinolone treatment-related tendon disease/disorder; congenital or history of QT prolongation; electrolyte disturbances, particularly in uncorrected hypokalemia; clinically relevant bradycardia & heart failure w/ reduced left ventricular ejection fraction; history of symptomatic arrhythmias. Pregnancy & lactation. Childn & adolescent <18 yr.

Hypersensitivity & allergic reactions, psychiatric reactions may occur after 1st dose. Discontinue treatment if anaphylactic reactions occur after the 1st dose; if signs of cardiac arrhythmia occur during treatment & perform ECG thereafter. Possible bullous skin reactions eg, SJS & TEN; consult a doctor immediately for continuation of treatment if skin &/or mucosal reactions occur. QT prolongation may lead to an increased risk for ventricular arrhythmias including Torsades de pointes. Patients w/ CNS disorders (eg, lowered seizure threshold, history of seizures, reduced cerebral blood flow, structural brain changes or stroke). Patients experiencing severe diarrhea during or after use. May worsen symptoms in patients w/ myasthenia gravis. Tendinitis & tendon rupture may occur w/in the 1st 48 hr of treatment. May increase risk of tendinopathy in elderly, during strenuous physical activity, in patients concomitantly treated w/ corticosteroids, w/ renal impairment or w/ solid organ transplant. Discontinue use at the 1st sign of pain or inflammation. Avoid excessive UV radiation or sun exposure during treatment. Not recommended in patients w/ complex pelvic inflammatory disease for whom an IV treatment is necessary. Combination therapy in patients w/ pelvic inflammatory disease caused by Neisseria gonorrhoeae. Not recommended for MRSA infection. Cases of sensory or sensorimotor polyneuropathy resulting in paresthesia, hypoaesthesia, dysaesthesia, or weakness; inform the doctor before continuing treatment if neuropathy symptoms eg, pain, burning, tingling, numbness, or weakness occur. Patients w/ psychotic disorders or history of mental illness; discontinue if psychiatric reactions occur after 1st dose. Concomitant use of oral hypoglycemic agent (eg, sulfonylurea) or insulin in the elderly diabetic patients; closely monitor blood glucose levels. Patients w/ or history of G6PD. Not to be used in patients w/ rare inherited disorders (eg, galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption). Immediately consult an ophthalmologist if visual disturbances or other eye-related effects occur. May impair ability to drive or operate machinery due to CNS reactions eg, dizziness & temporary or acute vision loss, as well as syncope. Fulminant hepatitis leading to liver damage (including fatal cases); perform LFTs if liver dysfunction occurs. Not recommended for patients w/ severe liver impairment (Child-Pugh C). Elderly w/ renal disorders who are unable to maintain adequate fluid intake.

Fungal superinfection; headache, dizziness; QT prolongation in patients w/ hypokalemia; nausea, vomiting, abdominal pain, diarrhea; increased transaminases; inj & infusion site reactions. Patients receiving consecutive IV/oral treatment: Increased γ-glutamyl-transferase.

Increased risk of ventricular arrhythmias, including Torsades de pointes w/ class IA (eg, quinidine, hydroquinidine, disopyramide) & class III (eg, amiodarone, sotalol, dofetilide, ibutilide) anti-arrhythmics, neuroleptics (eg, phenothiazines, pimozide, sertindole, haloperidol, sultopride), TCAs, certain antimicrobials (sparfloxacin, erythromycin IV, pentamidine, antimalarials particularly halofantrine), certain antihistamines (terfenadine, astemizole, mizolastine), cisapride, bepridil. May inhibit absorption w/ chelating agents (eg, Fe, Al, Mg). At least 6 hr administration interval in concomitant use w/ Mg or Al-containing antacids, didanosine, sucralfate, Fe- or Zn-containing medications. Increased anticoagulant activity w/ concurrent use of anticoagulants.

Quinolones

J01MA14 - moxifloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

K